Microsoft Excel LibreOffice Calc

Celgene Corp. (CELG)

Statement of Cash Flows
Quarterly Data

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Celgene Corp., Consolidated Statement of Cash Flows (quarterly data)

USD $ in millions

Microsoft Excel LibreOffice Calc
3 months ended Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Net income (loss) 1,073  1,082  1,045  846  (81) 988  1,101  932  429  171  598  801  561  (34) 356  719  614  509  598  280 
Depreciation 41  40  41  38  34  34  34  32  32  31  29  29  28  29  30  28  26  26  27  26 
Amortization 129  129  129  88  82  81  90  84  408  139  211  114  118  88  68  69  66  198  67  72 
Impairment charges 1  3  27  –  1,628  1  50  –  –  –  –  –  –  –  –  –  –  –  –  – 
Deferred income taxes 42  33  9  (52) (1,135) (9) (106) (80) (87) (90) (123) (43) 380  (161) (146) (107) (24) (68) (101) (80)
Change in value of contingent consideration and success payments (55) 97  7  (30) (1,425) 49  (13) 39  9  23  (44) 33  9  (7) (29) 19  38  2  1  9 
Gain on sale of business –  –  –  –  –  –  –  –  –  –  –  (38) –  –  –  –  –  –  –  – 
Net (gain) loss on sales of debt securities available-for-sale –  –  –  18  (43) (3) (15) –  –  –  (7) –  1  2  (86) –  1  1  3  – 
Fair value adjustments on equity investments 513  124  5  (959) –  –  –  –  –  –  –  –  –  –  –  –  –  –  –  – 
Share-based compensation expense 190  239  284  208  162  159  170  153  155  148  158  147  150  150  148  129  128  111  103  104 
Share-based employee benefit plan expense –  13  11  9  (1) 13  12  10  12  9  11  9  11  7  9  8  11  12  10  7 
Derivative instruments 14  (19) 30  (22) 58  (46) 53  7  (24) 208  (36) 21  8  (36) 3  (7) (49) (11) (18) 6 
Other, net (1) (4) (12) 2  (6) 28  (46) –  (1) (11) 4  (2) 1  22  (4) 1  (10) 1  (3) (1)
Accounts receivable 47  (68) (110) (47) (97) (64) (92) 17  (79) (63) (104) 23  (159) (5) (81) (60) (120) 16  (52) (10)
Inventory 51  45  (20) 6  (5) (5) (22) (10) 7  (17) (20) (26) (24) (8) (27) 7  (23) (15) (12) (7)
Other operating assets 319  (51) (152) (171) 212  (101) (213) 29  (43) 37  62  39  (309) 29  (20) (26) (3) 19  7  30 
Accounts payable and other operating liabilities 356  78  75  (219) 245  (191) 584  (365) 455  109  185  (130) 277  179  18  59  178  94  (132) 112 
Income tax payable (371) 156  (168) (10) 2,064  132  29  4  84  14  16  (3) 17  11  17  16  11  3  14  11 
Payment of contingent consideration –  –  –  (22) –  –  –  –  (9) –  –  –  –  –  –  –  (9) –  –  (5)
Deferred revenue (6) 27  28  (8) (3) 22  –  1  (5) 15  (5) 2  (12) 18  29  2  (3) 3  4  4 
Change in current assets and liabilities, excluding the effect of acquisitions and disposals 396  187  (347) (471) 2,416  (207) 286  (324) 411  95  135  (95) (209) 225  (65) (2) 30  121  (171) 135 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities 1,270  842  184  (1,171) 1,770  100  515  (79) 914  551  338  174  497  319  (72) 138  219  392  (82) 277 
Net cash provided by (used in) operating activities 2,343  1,924  1,229  (325) 1,689  1,088  1,616  853  1,343  723  936  975  1,058  285  284  857  833  901  516  557 
Proceeds from sales of debt securities available-for-sale 5  143  37  3,203  2,678  1,233  1,791  266  91  114  114  314  138  2,082  500  1,080  514  518  556  588 
Purchases of debt securities available-for-sale (435) (130) (48) (62) (1,762) (3,305) (1,620) (1,791) (720) (128) (147) (285) (190) (572) (448) (679) (524) (581) (790) (767)
Capital expenditures (98) (64) (80) (88) (103) (44) (70) (62) (66) (67) (44) (60) (141) (51) (53) (42) (49) (40) (37) (25)
Proceeds from sales of equity investment securities –  41  –  55  (12) 5  27  –  2  2  11  –  7  –  78  7  –  –  –  – 
Purchases of equity investment securities (73) (21) (37) (118) 297  (236) (79) (77) (10) (33) (10) (79) (56) (16) (173) (28) (9) (36) (5) (18)
Payments for acquisition of businesses, net of cash acquired –  –  –  (8,648) –  –  –  –  –  –  –  –  (116) (7,579) –  –  –  –  (710) – 
Other –  –  –  –  –  (27) (4) 4  –  (1) –  –  (3) (2) (3) –  (4) (21) –  1 
Net cash (used in) provided by investing activities (601) (31) (128) (5,658) 1,098  (2,374) 45  (1,660) (704) (112) (75) (110) (361) (6,138) (98) 338  (73) (159) (986) (220)
Payment for treasury shares –  –  (3,396) (2,700) (2,908) (114) (518) (293) (134) (320) (296) (1,410) (683) (577) (985) (1,013) (541) (252) (614) (1,569)
Proceeds from short-term borrowing –  780  3,114  1,815  –  –  –  –  100  –  –  –  3,881  1,260  881  90  130  202  775  1,460 
Principal repayments on short-term borrowing 1  (1,776) (2,119) (1,815) –  –  –  –  (100) –  –  –  (4,582) (1,421) (20) (190) (130) (294) (1,453) (1,135)
Proceeds from issuance of long-term debt –  –  –  4,452  2,972  496  –  –  –  –  –  –  –  7,913  –  –  –  –  2,471  – 
Principal repayments on current portion of long-term debt –  –  –  –  (1,404) (500) –  –  –  –  –  –  (514) –  –  –  –  –  –  – 
Net proceeds (payments) from common equity put options –  –  –  –  –  –  –  –  –  2  3  3  (19) 4  1  5  5  1  4  1 
Payment of contingent consideration –  –  –  (40) –  –  –  –  (41) –  –  –  –  –  –  –  (11) –  –  (15)
Net proceeds from share-based compensation arrangements 15  83  2  44  48  250  203  184  168  115  14  62  48  100  (10) 114  92  111  35  59 
Excess tax benefit from share-based compensation arrangements –  –  –  –  –  –  –  –  59  48  57  25  57  70  90  85  104  56  60  30 
Net cash provided by (used in) financing activities 16  (913) (2,399) 1,756  (1,292) 132  (315) (109) 53  (156) (223) (1,320) (1,813) 7,349  (43) (908) (352) (176) 1,279  (1,169)
Effect of currency rate changes on cash and cash equivalents (4) (3) (18) 33  7  5  41  19  (44) 5  (20) 20  (20) (10) 20  (40) (29) (43) 15  (6)
Net increase (decrease) in cash and cash equivalents 1,754  977  (1,316) (4,194) 1,502  (1,149) 1,387  (897) 647  459  618  (435) (1,136) 1,486  163  246  379  523  823  (838)

Based on: 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-07), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-10), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-07-28), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-10-28), 10-Q (filing date: 2014-07-29), 10-Q (filing date: 2014-04-29).

Item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Celgene Corp.’s net cash provided by (used in) operating activities increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Celgene Corp.’s net cash (used in) provided by investing activities increased from Q2 2018 to Q3 2018 but then declined significantly from Q3 2018 to Q4 2018.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Celgene Corp.’s net cash provided by (used in) financing activities increased from Q2 2018 to Q3 2018 and from Q3 2018 to Q4 2018.